News & Updates

Acne vulgaris linked to insulin resistance

12 Nov 2020 by

Levels of insulin resistance markers tend to be elevated in patients with acne vulgaris, supporting the association between acne vulgaris and insulin resistance, according to the results of a systematic review and meta-analysis.

Acne vulgaris linked to insulin resistance

12 Nov 2020

CTP-543 maintains hair regrowth in adults with hair loss

12 Nov 2020 by

Adults with moderate-to-severe alopecia areata (AA) had sustained or improved hair regrowth with the oral Janus kinase (JAK) inhibitor CTP-543, results of an open-label extension (OLE) study suggest.

CTP-543 maintains hair regrowth in adults with hair loss

12 Nov 2020

Oral selective JAK1 inhibitor a win in hidradenitis suppurativa

11 Nov 2020 by

INCB054707, an oral Janus kinase (JAK)1 inhibitor, shows promise in the treatment of moderate-to-severe hidradenitis suppurativa, reducing the abscess and inflammatory nodule count in addition to having an acceptable safety profile, according to data from two phase II trials.

Oral selective JAK1 inhibitor a win in hidradenitis suppurativa

11 Nov 2020

JAK inhibitors: Potential additions to chronic hand eczema treatment toolbox

10 Nov 2020 by

The search for chronic hand eczema relief has led to two different Janus kinase (JAK) inhibitors, one topical and the other oral, with both performing well in phase IIb trials reported during the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.

JAK inhibitors: Potential additions to chronic hand eczema treatment toolbox

10 Nov 2020

Abrocitinib shows promise in moderate-to-severe atopic dermatitis

10 Nov 2020 by

Patients with moderate-to-severe atopic dermatitis (AD) see clinical improvements in all body locations when treated with 100- or 200-mg doses of oral abrocitinib as compared with placebo, reports a new posthoc analysis presented at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).

Abrocitinib shows promise in moderate-to-severe atopic dermatitis

10 Nov 2020

New biologic enters fight against psoriasis

10 Nov 2020 by

A new monoclonal antibody which targets interleukin-23 (IL-23) is now available in Malaysia. Guselkumab (TREMFYA™, Janssen Pharmaceutical Companies of Johnson & Johnson) is a subcutaneously injected agent that blocks the body’s inflammatory pathway, namely, IL-23.

New biologic enters fight against psoriasis

10 Nov 2020

Brodalumab safe, effective in hidradenitis suppurativa

09 Nov 2020

Treatment with subcutaneous brodalumab is well tolerated in patients with hidradenitis suppurativa (HS), showing improvement in clinical outcomes and no serious adverse events, according to a recent study.

Brodalumab safe, effective in hidradenitis suppurativa

09 Nov 2020

Corticosteroids show promise in paediatric DRESS

09 Nov 2020

Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.

Corticosteroids show promise in paediatric DRESS

09 Nov 2020

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

09 Nov 2020 by

The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of nonsmall cell lung cancer (NSCLC) commonly triggers cutaneous side effects, which often leads to drug reductions or discontinuation, reports a new study at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

09 Nov 2020

Baricitinib maintains clear skin in AD patients over 68 weeks

07 Nov 2020 by

Continuous treatment with baricitinib maintains clear or almost clear skin in patients with moderate-to-severe atopic dermatitis (AD) over 68 weeks, according to long-term results from the BREEZE-AD3 study presented during EADV 2020.

Baricitinib maintains clear skin in AD patients over 68 weeks

07 Nov 2020

News & Updates

Filter by Specialty:

Specialty:

Acne vulgaris linked to insulin resistance

Acne vulgaris linked to insulin resistance

CTP-543 maintains hair regrowth in adults with hair loss

CTP-543 maintains hair regrowth in adults with hair loss

Oral selective JAK1 inhibitor a win in hidradenitis suppurativa

Oral selective JAK1 inhibitor a win in hidradenitis suppurativa

JAK inhibitors: Potential additions to chronic hand eczema treatment toolbox

JAK inhibitors: Potential additions to chronic hand eczema treatment toolbox

Abrocitinib shows promise in moderate-to-severe atopic dermatitis

Abrocitinib shows promise in moderate-to-severe atopic dermatitis

New biologic enters fight against psoriasis

New biologic enters fight against psoriasis

Brodalumab safe, effective in hidradenitis suppurativa

Brodalumab safe, effective in hidradenitis suppurativa

Corticosteroids show promise in paediatric DRESS

Corticosteroids show promise in paediatric DRESS

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

Baricitinib maintains clear skin in AD patients over 68 weeks

Baricitinib maintains clear skin in AD patients over 68 weeks